STT-003 is under clinical development by Stcube and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STT-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STT-003 is under development for the treatment of head and neck cancer, melanoma, colorectal cancer and lung cancer. It acts by targeting BTN1A1.It is administered through intravenous route.
Stcube is a developer and supplier of biopharmaceuticals. The company manufactures and supplies information technology products. It offers drug development, and novel anti cancer drugs system. STCube provides novel anticancer drugs for radiation sensitization and immune modulation. The company offers products which includes immuno modulator and upgraded targeted therapy. It provides antiviral treatment. It also provides research and development facilities to various universities and research institutes. It operates through its facilities located in South Korea and the US. STCube is headquartered in Seoul, South Korea.
For a complete picture of STT-003’s drug-specific PTSR and LoA scores, buy the report here.